Our team of pathologists represent the various pathology subspecialties across both the clinical and research sectors. In addition to their research investigational interests, they also espouse the urgency of a clinical pathologist. Each of our pathologists are encouraged to explore their interest areas and formulate services that benefit our clientele. Please contact us for a consultation with our pathologists.

Anatomic Pathologists

MarkKockxMark Kockx, MD, PhD. Founder, Chief Executive Officer & Chief Medical Officer

Dr. Mark Kockx founded Histogenex Laboratories in 2001. At the University of Antwerp, Belgium, Dr. Kockx pioneered methodologies to elucidate apoptotic and cytostatic response of cancer patients after treatments with targeted therapies. His subsequent collaborations with global pharmaceutical companies led to the founding of Histogenex Laboratories.

Dr. Kockx is an internationally recognized pathologist-scientist who has operated on the forefront of personalized medicine developments. He continues to lead initiatives to standardize biomarker analysis practices in addition to adapting novel technologies. Dr. Kockx has been extensively involved with the clinical trials that led to the approval of well-known targeted therapies such as EGFR, BRAF and MEK inhibitors. His current passions are two fold. He is introducing practices and workflows for next generation IHC, combining innovations of multiplex staining, quantification and image capture. He has also developed an Immunomics program, a state of the art biomarker program that supports the evolving and numerous needs of immunotherapy development.



Diana Stanoeva, MD, PhD., Anatomic Pathologist (Expertise: Tissue MicroArray Applications & Urology)

Diana Stanoeva, MD, PhD is a surgical pathologist with a strong background in perinatal medicine, especially in the field of placental pathology and intrauterine fetal death. She conducted an extensive tissue micro-array research focused on unsuccessful pregnancies investigating the implication of apoptosis in recurrent fetal loss. At HistoGeneX she participates in the development of IHC biomarker assays and provides pathology assessments of immunotherapy biomarkers such as PD-L1.


IMG 7466

Emil Nakov M.D., Anatomic Pathologist

Dr. Emil Nakov works in HistoGeneX's clinical pathology department. His area of expertise is in oncopathology, examining samples from the breast, the lung, and the urogenital and gastrointestinal systems. He also specializes in neuroendocrine pathology. Previously, Dr. Nakov previously worked in the Department of Clinical Pathology in the Military Medical Academy of Bulgaria. He has examined thousands of biopsy and cytology slides and regularly performed intraoperative express examinations and autopsies.



Wim Waelput, MD, PhD., Molecular Pathologist (Expertise: Digital Pathology & Imaging)

Dr. Wim Waelput is our resident pathologist who carries a deep interest in digital pathology and imaging. He has accumulated a large body of research and clinical experience through the university hospitals in the Belgium (Brussels, Antwerp and Ghent). In addition to reviewing and scoring novel biomarkers in histopathology, Dr. Waelput has invented digital pathology solutions that greatly facilitate acquisition, management, analysis and collaboration of tissue images. HistoGeneX has implemented these solutions as part of its research and clinical trial services.



Sabine Declerq, MD, PhD., Anatomic Pathologist 

Dr. Declerq serves HistoGeneX as an anatomic pathologist and has reviewed, analyzed and scored thousands of clinical trial slides. These activities include review of H&E, IHC and FISH -stained slides. In addition, Dr. Declerq assesses tumor material sufficiency and defines regions on glass slides for subsequent macrodissection. Dr. Declerq also serves as head of pathology at neighboring Middleheim Hospital.


Surgical Pathologists

PeterVPeter Vermeulen, MD, PhD., Surgical Pathologist

Dr. Peter Vermeulen spans histological and molecular technologies and has authored nearly 200 publications. Peter will lead our Patho-Imaging laboratory section and will also serve as a Principle Investigator for various studies. He is certified in multiple subspecialities and has deep clinical (especially breast cancer) and research (especially tumor vascularization) experience.

Veterinary Pathologists

IsoldeIsolde Debyser DVM, PhD., Veterinary Pathologist (Expertise: Veterinary & Toxicology Pathology)

Dr. Isolde Debyser's training in veterinary and toxicology pathology has proven invaluable in early research projects and Phase I clinical trials. Dr. Debyser's activities include reviewing target expression and pharmacodynamic biomarker expressions in xenograft and other animal tissues. 


Clinical Pathologists

Isabelle-Vanden-BemptIsabelle Vanden Bempt, PharmD, PhD. Molecular Pathologist 

Dr. Isabelle Vanden Bempt serves as a clinical pathologist, Section Head for our Molecular Pathology services, and as an investigator in clinical trials. Dr. Vanden Bempt oversees our RNA and DNA based services, in addition to our panel of epigenetic expression biomakers. She is interested in hematopathologic malignancies and exploring novel molecular technologies.



Walter Verstrepen PharmD, PhD., Clinical Pathologist 

Dr. Walter Vestrepen provides supportive services for our molecular pathology offering. In addition he heads the molecular pathology department at ZNA (ZeikenhuisNetwerk Antwerpen). Dr. Verstrepen previously held positions at the University of Antwerp in the department of Nephrology. He conducted research on growth factor expression and has served as an investigator in clinical trials.



Dirk Hendriks PharmD, PhD., Clinical Pathologist, Founder, Chief Financial Officer & Director of Strategic Business Development 

Dr. Dirk Hendriks provides supportive services for clinical pathology. In addition, as the Head of the Commission of Clinical Pathology at the University of Antwerp, he heads the training program for clinical pathology students in training. He maintains an active lecturing schedule covering medical biochemistry, hematologic pathophysiology , clinical pathology and laboratory management. At the University of Antwerp, Professor Hendriks has a track record in the discovery of novel fibrinolytic mechanisms and the development of drugs for the treatment of thrombo-embolic diseases.